Biotech Values

[DewDiligence]

BMY takes global license to IMTX’s TCR-bispecific program—$150M up-front:

https://finance.yahoo.com/news/immatics-bristol-myers-squibb-enter-115900405.html

Under the terms of the agreement, Immatics will receive an upfront payment of $150 million as well as up to $770 million in development, regulatory and commercial milestone payments, in addition to tiered double-digit royalty payments on net sales of IMA401. Immatics retains the options to co-fund U.S. development in exchange for enhanced U.S. royalty payments and/or to co-promote IMA401 in the US.

p.s. This is the second collaboration between these companies; the first was inherited from Celgene.